Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Trial Scheme of Xinnaoning Capsule

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03914131
Recruitment Status : Recruiting
First Posted : April 15, 2019
Last Update Posted : April 15, 2019
Sponsor:
Information provided by (Responsible Party):
Beijing Duheng for Drug Evaluation and Research Co., Ltd. (DDER)

Brief Summary:
This study is a randomized, double-blind, parallel-controlled, multicenter clinical study to evaluate the efficacy and safety of Xinnaoning capsule in the treatment of chronic stable angina pectoris (Qi stagnation and blood stasis syndrome).

Condition or disease Intervention/treatment Phase
Chronic Stable Angina Pectoris Qi Stagnation and Blood Stasis Syndrome Drug: Xinnaoning Capsule Other: Xinnaoning Capsule Simulator Phase 4

Detailed Description:
Coronary heart disease angina pectoris is a kind of heart disease caused by myocardial ischemia and anoxia caused by coronary atherosclerosis. It belongs to the category of "chest obstruction" and "heartache" in traditional Chinese medicine. One of its common pathogenesis is stagnation of Qi and blood stasis, blockage of blood vessels, so it should be treated by activating blood circulation and removing blood stasis, dredging channels and collaterals, as well as tranquilizing Qi and tranquilizing spirit, in order to achieve the goal of blood stasis to remove new life and nourish the blood vessels of viscera and viscera. Xinnaoning Capsule (Chinese medicine approved character: Z20025697) is produced by Guizhou Jingcheng Pharmaceutical Co., Ltd. It has the functions of activating blood circulation, promoting Qi circulation, dredging collaterals and relieving pain.Xinnaoning Capsule has not had any adverse reactions for many years after it was put on the market. In this study, a randomized, double-blind, placebo-controlled, multi-center, efficacy test design was used to evaluate the efficacy and safety of Xinnaoning Capsule in the treatment of chronic stable angina pectoris (Qi stagnation and blood stasis syndrome) .

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 240 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: To Evaluate the Efficacy and Safety of Xinnaoning Capsule in Treating Chronic Stable Angina Pectoris (Qi Stagnation and Blood Stasis Syndrome) : a Randomized, Double-blind, Parallel Controlled, Multi-center Clinical Study
Actual Study Start Date : May 15, 2018
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : April 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Angina

Arm Intervention/treatment
Experimental: study group

Introduction period: 2 weeks, time window (±2 days). Dosage regimen: Take Xinnaoning Capsule Simulator 3 tablets per time, 3 times per day, orally, after meals.

The treatment period: 12 weeks, time window (±4 days). Dosage regimen:Take Xinnaoning Capsule 3 tablets per time, 3 times per day, orally, after meals.

Dosage form:Capsule

Drug: Xinnaoning Capsule
Xinnaoning Capsule used in study group(treatment period) is the true drug that the investigators are to evaluate.
Other Name: Xinnaoning

Other: Xinnaoning Capsule Simulator
Xinnaoning Capsule Simulator used in control group and introduction period(both groups) is the placebo to reduce the risk of bias.
Other Name: placebo

Placebo Comparator: control group

Introduction period: 2 weeks, time window (±2 days). Dosage regimen: Take Xinnaoning Capsule Simulator 3 tablets per time, 3 times per day, orally, after meals.

The treatment period: 12 weeks, time window (±4 days). Dosage regimen:Take Xinnaoning Capsule Simulator 3 tablets per time, 3 times per day, orally, after meals.

Dosage form:Capsule

Other: Xinnaoning Capsule Simulator
Xinnaoning Capsule Simulator used in control group and introduction period(both groups) is the placebo to reduce the risk of bias.
Other Name: placebo




Primary Outcome Measures :
  1. the changes of curative effect of angina pectoris symptoms [ Time Frame: Visit1:introduction period,-14±2days; Visit2:treatment period,-4~0day; Visit3:treatment period,4weeks±4days; Visit4:treatment period,8weeks±4days; Visit5:treatment period, 12weeks±4days ]
    The number of angina attacks, duration, degree of pain, and the dosage of nitroglycerin are used as indicators for scoring. Score ranges 0-15, the higher the score, the more severe the angina.


Secondary Outcome Measures :
  1. Therapeutic effect of TCM syndromes [ Time Frame: Visit1:introduction period,-14±2days; Visit2:treatment period,-4~0day; Visit3:treatment period,4weeks±4days; Visit4:treatment period,8weeks±4days; Visit5:treatment period, 12weeks±4days ]
    The main symptoms of Qi stagnation and blood stasis syndrome are chest pain, chest tightness, secondary symptoms such as palpitation, shortness of breath, chest swelling, fatigue, dark lips, dizziness, veins at the base of tongue, irritability, etc. The severity and presence of these symptoms are used as criteria for scoring. Score ranges 0-28.The higher the score, the more serious it is.

  2. Grading changes of severity of angina pectoris [ Time Frame: Visit1:introduction period,-14±2days; Visit2:treatment period,-4~0day; Visit3:treatment period,4weeks±4days; Visit4:treatment period,8weeks±4days; Visit5:treatment period, 12weeks±4days ]
    Reference to Canadian Cardiovascular Society (CCS) Angina Severity Classification Standard。Ⅰ:General physical activity does not cause angina pectoris, such as walking and going upstairs, but tension, rapid or sustained exertion can cause the onset of angina pectoris.Ⅱ:Daily physical activity is slightly restricted. Walking fast or upstairs, climbing high, walking after meals or upstairs, walking in cold or wind, and emotional excitement can cause angina or only occur within a few hours after waking up. It is limited to walk more than 200 meters or climb stairs above one floor at normal speed.Ⅲ:Daily physical activity is obviously limited, and angina pectoris can occur when walking 100-200 m at normal speed or climbing a staircase.Ⅳ:Angina symptoms can occur when you are slightly active or at rest.

  3. Changes in the number of angina attacks per week [ Time Frame: through study completion, an average of 14 weeks ]
    Frequency of angina pectoris episodes per week

  4. Nitroglycerin dosage [ Time Frame: through study completion, an average of 14 weeks ]
    basic treatment

  5. Seattle Angina Questionnaire,SAQ [ Time Frame: Visit1:introduction period,-14±2days; Visit2:treatment period,-4~0day; Visit3:treatment period,4weeks±4days; Visit4:treatment period,8weeks±4days; Visit5:treatment period, 12weeks±4days ]
    The Seattle Angina Questionnaire (SAQ) measured a total of L9 problems,including physical activity limitation, stable state of angina, frequency of angina attack, satisfaction with treatment, and knowledge of disease. A kind of Assessment of Seattle Scale: The Seattle Angina Scale was divided into 5 items and 19 items: Physical Activity Restriction (PL, Question 1), Angina Stable State (AS, Question 2), Angina Attack (AF, Question 3-4), Treatment Satisfaction (TS, Question 5-8), Disease Cognition (DS, Question 9-11), 19 items of 5 items and the total score of SAQ. The formula is transformed into standard integral, standard integral = (actual score - the lowest score in this respect) / (the highest score in this respect - the lowest score in this respect) * 100, the higher the score, the better the quality of life and the state of body function of patients.

  6. Blood homocysteine [ Time Frame: visti1:treatment period,-4~0day; Visit2:treatment period,12weeks±4days ]
    The changes of blood HCY before and after treatment are compared between the two groups.

  7. Incidence of cardiovascular events [ Time Frame: Visit1:treatment period,-4~0day; Visit2:treatment period,4weeks±4days; Visit3:treatment period,8weeks±4days; Visit4:treatment period, 12weeks±4days ]
    Sudden cardiac death, acute myocardial infarction, heart failure, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, malignant arrhythmia, cardiogenic cerebrovascular accident, angina pectoris requiring hospitalization, etc.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years to 79 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Refer to the Guidelines for Diagnosis and Treatment of Chronic Stable Angina issued by the Chinese Medical Association in 2007, 2012ACP/ACCF/AHA/AATS/PCNA/STS (Guidelines for Diagnosis and Management of Stable Ischemic Heart Disease: American Heart Foundation/American Heart Association/American Medical Association/American Thoracic Surgery Association/American Association for Cardiovascular Preventive Nursing/American Association for Cardiovascular Angiography and Intervention/American Thoracic Association The Diagnosis of Stable Ischemic Heart Disease: Guidelines for Clinical Practice, Guidelines for the Management of Stable Coronary Artery Diseases in 2013 ESC, which can diagnose coronary heart disease in accordance with any of the following:

    1. Has a clear history of old myocardial infarction, or PCI history, or bypass history
    2. Coronary angiography (results indicate at least one coronary artery stenosis with stenosis (>50%) or coronary CTA suggests stenosis with stenosis (>50%)
  • Those who met the diagnostic criteria of chronic stable angina pectoris: those who had a history of angina pectoris more than 1 month and had no significant changes in the degree, frequency, nature and inducing factors of angina pectoris
  • The severity of angina pectoris of the Canadian Cardiovascular Society (CCS) was classified as Grade I to Grade III, and angina pectoris occurred more than twice a week
  • The syndrome differentiation of TCM is Qi stagnation and blood stasis syndrome
  • Age ranges from 30 to 79 years old
  • Sign the informed consent

Exclusion Criteria:

  • Severe cardiopulmonary insufficiency (grade III, IV, severe abnormal pulmonary function);
  • Poor control of hypertension (systolic blood pressure (> 160 mmHg) or diastolic blood pressure (> 100 mmHg) after treatment;
  • Complicated with liver and kidney function damage, ALT, AST (> 1.5 times of the upper limit of normal value), or Cr (> the upper limit of normal value), combined with hematopoietic system and other serious primary diseases;
  • Acute myocardial infarction within 3 months after interventional therapy;
  • Cardiac pacemaker;
  • Pregnancy, lactation or pregnancy planners;
  • Anaphylactic constitution or allergic to known ingredients of research drugs;
  • Chest pain caused by other causes (moderate anemia, hyperthyroidism, etc.)
  • Those who participated in other clinical drug trials within one month;
  • According to the judgement of the researchers, it is not advisable to participate in clinical researchers.
  • Other factors affecting ST-T changes in ECG, such as myocardial hypertrophy, left bundle branch block, etc.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03914131


Contacts
Layout table for location contacts
Contact: Fengqin Xu, Doctor 010-62835113 ext 010-62835113 18800021979@163.com
Contact: Chunsheng Qiao 010-58462584 ext 010-58462584 qiaocs@drugevaluation.cn

Locations
Layout table for location information
China, Beijing
Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine Recruiting
Beijing, Beijing, China, 100091
Contact: Fengqin xu, Doctor    010-62835113    18800021979@163.com   
Sponsors and Collaborators
Beijing Duheng for Drug Evaluation and Research Co., Ltd. (DDER)
Investigators
Layout table for investigator information
Principal Investigator: Fengqin Xu, Doctor Xiyuan Hospital of China Academy of Chinese Medical Sciences
  Study Documents (Full-Text)

Documents provided by Beijing Duheng for Drug Evaluation and Research Co., Ltd. (DDER):
Study Protocol  [PDF] January 26, 2018
Informed Consent Form  [PDF] January 26, 2018


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Beijing Duheng for Drug Evaluation and Research Co., Ltd. (DDER)
ClinicalTrials.gov Identifier: NCT03914131     History of Changes
Other Study ID Numbers: DHZD-XNNJN-001
First Posted: April 15, 2019    Key Record Dates
Last Update Posted: April 15, 2019
Last Verified: April 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Blind Loop Syndrome
Angina Pectoris
Angina, Stable
Syndrome
Disease
Pathologic Processes
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Chest Pain
Pain
Neurologic Manifestations
Signs and Symptoms
Malabsorption Syndromes
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Metabolic Diseases